Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE ... grew by 45% year-over-year through the final quarter of 2024. However, the company does not ...

Lilly's sales, too, grew 45% in the quarter. And this implies that in the final quarter of the year ... in 2025 and Hold Forever. Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity ...

Recent financial results show significant revenue and profit growth, driven by drugs like Zepbound and Mounjaro ... the final quarter of the 2024 fiscal year. Fundamentally speaking, Eli Lilly ...

For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1. ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly ... things went well too. Mounjaro had a very strong ...

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiveness overseer NICE.

Eli Lilly will spend ... device assembly, and packaging for medicines across multiple therapeutic areas," according to a company statement. Sales of both Mounjaro and Zepbound have been held ...

On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co ... versions of tirzepatide, Mounjaro® (for diabetes) and ...